Edit

Treo Ventures

https://treovp.com

Last activity: 12.07.2025

Active

Invests in categories: MedTechTechnologyHardwareHealthTechProductWearablesDevelopmentEquipmentHumanAgency

Strategic Healthcare Investment Partners (S.H.I.P.) is now Treo Ventures.

We focus on medical device and digital health innovation with significant clinical impact. We invest through our offices in Silicon Valley, USA , and Dublin, Ireland.

News

Portfolio

Persons

Mentions

Location: United States, California, Santa Clara

Employees: 1-10

Investment Type: Venture Capital

Investment Stage: Series C

Portfolio 9

Date	Name	Website	Total Raised	Location
08.01.2025	InterVene	intervene-med.com	$13M	United Sta...
08.07.2021	Neuspera M...	neuspera.com	$140M	United Sta...
-	NeoChord	neochord.com	$97.6M	United Sta...
-	NuXcel	nuxcel.com	-	-
-	Intuity Me...	presspogo.com	$261M	United Sta...
-	ShiraTroni...	shiratronics.com	$102M	United Sta...
-	Noctrix He...	noctrixhealth.com	$57M	United Sta...
-	BAROSTIM T...	cvrx.com	$265.6M	United Sta...
-	Hyalex	hyalex.com	$49M	United Sta...

Persons 4

Date	First Name	Last Name	Title	LinkedIn	Twitter	Email	Location
-	Dave	Shanahan, ...	Venture Pa...	linkedin.c...	-	-	-
-	Mudit	K. Jain, P...	Founder an...	linkedin.c...	-	-	-
-	Tracy	Pappas	General Pa...	linkedin.c...	-	-	-
-	Brad	H. Vale, P...	Founder an...	linkedin.c...	-	-	-

News 65

Date	Title	Description
26.06.2025	Avivomed Names Dan Brounstein as Next Chief Executive Officer	-
18.06.2025	Neuspera Medical Receives FDA Approval for First Integrated Sacral Neuromodulation (iSNM) System for Urinary Urge Incontinence	-
20.05.2025	Hyalex Orthopaedics Receives FDA Approval of IDE Supplement, Expanding the Early Feasibility Study to a Pivotal Trial of Cutting-Edge Freestyle Knee Implant	-
18.05.2025	2025 Best Tech Startups in Minnesota	-
08.05.2025	CVRx Reports First Quarter 2025 Financial and Operating Results	-
08.04.2025	SecondWave Systems raises $7M Series A to Accelerate Clinical Development of a Novel Ultrasound-Based Anti-Inflammatory Therapy	-
26.02.2025	Neuspera Medical Announces Landmark Six-Month Clinical Trial Results for the First Battery-Free Percutaneous Sacral Neuromodulation (pSNM) System for Urgency Urinary Incontinence Management	-
04.02.2025	CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results	-
03.12.2024	ShiraTronics Initiates IDE Pivotal Study of Implantable Neuromodulation Therapy for Chronic Migraine	-
04.11.2024	CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025	-
29.10.2024	CVRx Reports Third Quarter 2024 Financial and Operating Results	-
09.10.2024	ShiraTronics Raises $66 Million in Oversubscribed Series B Financing to Advance Pioneering Treatment for Chronic Migraine	-
07.10.2024	InterVene, Inc. Announces $13 Million Series A Financing to Advance Recana™ System Through US Market Clearance	-
03.10.2024	Noctrix Health Announces Favorable Inclusion of Nidra Tonic Motor Activation (TOMAC) Therapy in New American Academy of Sleep Medicine (AASM) Clinical Practice Guidelines for Restless Legs Syndrome (R...	-
12.09.2024	CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim	-
12.09.2024	Neuspera Medical, Inc. Welcomes Bunty Banerjee as Its First Chief Operating Officer	-
19.08.2024	Noctrix Health Announces New CMS Reimbursement Codes for Payment for Nidra Tonic Motor Activation (TOMAC) Therapy for Restless Legs Syndrome (RLS)	-
02.08.2024	CVRx Announces Increased Inpatient Payment for Barostim Procedure	-
29.07.2024	CVRx Reports Second Quarter 2024 Financial and Operating Results	-
26.07.2024	Neuspera Medical, Inc. Reaches Significant Milestone: Final Patient has Completed Primary Endpoint Visit in the SANS-UUI Pivotal Clinical Trial	-
16.07.2024	ShiraTronics Unveils Data on their Neurostimulation System for Chronic Migraine	-
15.07.2024	Neuspera Medical Raises $23 Million in Series D Financing	-
30.04.2024	CVRx Reports First Quarter 2024 Financial and Operating Results	-
22.04.2024	iVEAcare Launches with $27.5 Million in Series A Funding from Leading Medtech Investors	-
22.04.2024	Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System	-
22.02.2024	NeoChord, Inc. Appoints New Chief Executive Officer to Lead Commercialization Efforts and Study Novel First-Line Therapy for Mitral Valve Regurgitation	-
06.02.2024	ShiraTronics Completes Australian Pilot Study Enrollment; Prepares for Pivotal Clinical Study	-
31.01.2024	CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer	-
25.01.2024	CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results	-
16.01.2024	Noctrix Health Secures $40 Million Series C Financing to Commercialize Novel Device Treatment For Restless Legs Syndrome (RLS)	-
26.12.2023	CVRx receives FDA approval for expanded labeling of Barostim	-
19.12.2023	ShiraTronics Announces Landmark Achievement: World’s First Implant of its Innovative Chronic Migraine System	-
06.12.2023	Neuspera Medical, Inc. Completes Patient Enrollment and Implants for the SANS-UUI Pivotal Clinical Trial	-
29.11.2023	ShiraTronics Announces Groundbreaking Milestone: World’s First Trial Phase Procedures for their Chronic Migraine Therapy System in Australian Pilot Study	-
26.10.2023	CMS Increases Outpatient Payment for Barostim Procedure	-
26.10.2023	CVRx Reports Third Quarter 2023 Financial and Operating Results	-
26.07.2023	Noctrix Health announces publication of landmark results from randomized clinical trial and long-term extension study of its revolutionary Tonic Motor Activation (TOMAC) therapy for Restless Legs Synd...	-
25.07.2023	CVRx Reports Second Quarter 2023 Financial and Operating Results	-
22.06.2023	CVRx Set to Join Russell 2000 & 3000 Indexes	-
09.05.2023	Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy	-
27.04.2023	CVRx Reports First Quarter 2023 Financial and Operating Results	-
18.04.2023	Neuspera Medical® Announces FDA Clearance of its System for Peripheral Nerve Stimulation	-
06.03.2023	Neuspera Hires Courtney Lane to Lead Clinical and Regulatory Affairs	-
26.01.2023	CVRx Reports Fourth Quarter and Full Year 2022 Financial and Operating Results	-
07.11.2022	Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes	-
19.10.2022	NeoChord Announces Positive 1-year Follow-Up Data with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor	-
13.10.2022	Neuspera Medical® announces first successful implant of the Nuvella™ System in the second phase of its sans-UUI IDE Clinical Trial	-
15.09.2022	ShiraTronics, Inc. Welcomes New CEO	-
14.06.2022	Neuspera Medical® Announces Second Phase of SANS-UUI IDE Clinical Trial with the Nuvella™ System	-
09.06.2022	Neuspera Medical® Appoints Steffen Hovard as CEO	-
28.02.2022	NeoChord’s Transfemoral Mitral Valve Repair System Wins CRT 2022 Best Innovation Competition	-
06.07.2021	Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx	-
29.06.2021	CVRx, Inc. Announces Upsized Pricing of Initial Public Offering	-
10.04.2021	NeoChord Announces Successful Completion of First in Human Procedure with its NeoChord NeXuS Transcatheter Mitral Chordal Repair Technology	-
08.02.2021	ShiraTronics, Inc. Receives FDA Breakthrough Device Designation for Chronic Migraine Neurostimulation	-
12.01.2021	Strategic Healthcare Investment Partners Closes $128M Debut Medical Devices and Digital Health Venture Fund and Rebrands Itself as Treo Ventures.	-
11.01.2021	Noctrix Health, Inc. Completes $17 Million Series B Financing.	-
05.01.2021	CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing.	-
03.12.2020	CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status.	-
07.07.2020	CVRx® Raises $50 Million in New Equity Financing.	-
26.03.2020	ShiraTronics, Inc. Completes $3 Million Additional Series A Financing.	-
25.10.2019	ShiraTronics, Inc. Completes $33M Million Series A Financing.	-
16.08.2019	CVRx® Receives FDA Approval for World’s First Heart Failure Neuromodulation Device.	-
02.05.2019	Hyalex Orthopaedics, synthetic cartilage company, adds new funding; expanding Series A total to $33MM.	-
02.05.2019	NeoChord Raises Additional Financing to Drive Catheter‐based Program Development, Bringing Total Series D Funding to over $32 Million.	-

Mentions in press and media 1

Date	Title	Description
06.07.2021	Treo Ventures Announces the Successful IPO of its Portfolio Company CVRx® (NSDQ: CVRX)	SANTA CLARA, Calif. and DUBLIN, July 6, 2021 /PRNewswire/ -- Treo Ventures portfolio company CVRx, Inc. announced the upsized pricing of its initial public offering on the Nasdaq Global Select Market. Treo led the pre-IPO round in July 2020...

Treo Ventures

Portfolio 9

Persons 4

News 65

Mentions in press and media 1

Reviews 0